4,960 Shares in GSK plc (NYSE:GSK) Acquired by Farmers Trust Co.

Farmers Trust Co. acquired a new position in GSK plc (NYSE:GSK) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,960 shares of the pharmaceutical company’s stock, valued at approximately $203,000.

A number of other hedge funds have also recently added to or reduced their stakes in GSK. Register Financial Advisors LLC acquired a new position in GSK in the first quarter worth approximately $31,000. Ashton Thomas Private Wealth LLC acquired a new position in GSK in the second quarter worth approximately $37,000. Richardson Financial Services Inc. acquired a new position in GSK in the fourth quarter worth approximately $40,000. PrairieView Partners LLC bought a new stake in GSK during the second quarter worth approximately $47,000. Finally, Triad Wealth Partners LLC bought a new stake in GSK during the second quarter worth approximately $49,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Insider Buying and Selling at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.00% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on GSK. Citigroup raised GSK to a “strong-buy” rating in a research report on Monday, June 24th. Berenberg Bank raised GSK to a “strong-buy” rating in a report on Thursday, June 20th. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Argus raised GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Jefferies Financial Group lifted their price objective on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, GSK has a consensus rating of “Buy” and an average price target of $50.00.

GSK Trading Up 1.2 %

GSK stock traded up $0.45 during midday trading on Friday, reaching $38.82. The stock had a trading volume of 6,582,359 shares, compared to its average volume of 3,590,294. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. The business has a fifty day simple moving average of $41.57 and a two-hundred day simple moving average of $41.51. GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92. The firm has a market cap of $80.45 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 1.31 and a beta of 0.65.

GSK (NYSE:GSK) last released its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. As a group, research analysts expect that GSK plc will post 4.17 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be paid a $0.3843 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, August 16th. This represents a $1.54 annualized dividend and a yield of 3.96%. GSK’s payout ratio is presently 54.71%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.